 Hello, everybody. Welcome back to Investor Intel. I'm Peter Clausi. Today, an old friend and recurring guest, Thomas Smink from Hemostamics. Good afternoon, Peter. I always get that name wrong, Hemostamics. Yeah, Hemostamics. Thank you. Traded says HEM on the Venture Exchange. So let's get right into it. Could you please give us an update on the clinical trials for ACP? Yes, so we are completing a source document verification process, which is exactly like an audit of a financial statement, where you go back and you literally have to prove every piece of data that is in a database by looking at the source document, verifying that the data exists on the source document, so that when you go to the lockdown, you can do an analysis of real data. And so we're at about 60% completion of the source document verification. What's our timeline for completion? Well, it's its painstaking process because we're going back in some cases back to 2014. So it's got to be done right. It has to stand the test of a true audit by the FDA. So are we talking 2021, 2022? Oh no, definitely in 2021. But it's taking longer than even I had anticipated, quite a bit longer. Roughly 58 million shares issued note standing? Yes. You have a close to a million? Yes. Is it public who your largest shareholders are? Yes. Peter Lacey, our chairman, is now by far and on a fully diluted basis would own more than 20%, just over 20%. So what should we expect for the rest of 2021? And what's going to be exciting about 2022? We have so much coming in the pipeline, Peter, that I have a series of press releases starting in September when everybody's back to work. That is, I think, going to be very exciting for our shareholders who have been waiting a long time. That they have, but you were instrumental in making the turnaround happen. And now you're driving that with your team. So congratulations to you. Thank you. Yeah, I know it's a great team. And it's about to get a lot bigger and greater. So there's lots of things on the come. September, October, November is going to be the turnaround that we've been all anticipating for Hemostemics. Well, let's book you in for October and we'll catch up, see how you're doing. Sounds great. I thank you for your time. Hemostemics treats as HEM on the venture exchange, Thomas Smink, saved to the company. I'm Peter Clausi, signing off from Investor Intel. Thanks, Peter.